When a developer of a CD19-directed cytolytic antibody for B-cell Lymphoma engaged Premier Research to assist with screening and enrollment in a global Phase 2 study, the Premier project team devised an operational strategy with a goal to exceed expectations. Despite several challenges, the enrollment was completed three months ahead of schedule thanks to consistent communication and collaboration. Patients also demonstrated remarkable results to the treatment, with five showing complete response to the therapy and maintaining remission for at least eight years.
